Altevax Biotech
Created in 2016
- BETA
Up & running (A)
Existing signals show a regular activity Social networks
751Activities
Technologies
Entity types
Location
55 Av. Marceau, 75116 Paris, France
Paris
France
Employees
Scale: 2-10
Estimated: 6
SIREN
823688502Engaged corporates
11
3 5Added in Motherbase
1 year, 3 months ago
biotech Value proposition
Altevax is developing a disruptive immunotherapy technology against cancer
Altevax is developing a powerful pioneering immunotherapy technology against cancer. Its patented melanin-based technology has been proven in pre-clinical trials to boost an antigen-specific immune response with Cytotoxic T-lymphocytes (CD8+ Killer T cells), the body’s most powerful defenders. The Altevax immunotherapy technology works with a wide range of peptides. The Altevax technology is complementary to other anti-cancer immune technologies, such as anti PD1s.
Altevax is developing an immunotherapy against glioblastoma, currently in advanced pre-clinical development, with Phase 1/2a expected in early 2024.
Altevax's partnership with Assistance Publique Hôpitaux de Paris and other research institutions enables it to leverage their resources and accelerate clinical trials.
Cancer vaccines, immunotherapy, melanin, therapeutic vaccines, Peptidic vaccines, infectious diseases, CD8 Killer T cells, and Immuno-oncologyOriginal language
Altevax is developing a disruptive immunotherapy technology against cancer
Altevax is developing a powerful pioneering immunotherapy technology against cancer. Its patented melanin-based technology has been proven in pre-clinical trials to boost an antigen-specific immune response with Cytotoxic T-lymphocytes (CD8+ Killer T cells), the body’s most powerful defenders. The Altevax immunotherapy technology works with a wide range of peptides. The Altevax technology is complementary to other anti-cancer immune technologies, such as anti PD1s.
Altevax is developing an immunotherapy against glioblastoma, currently in advanced pre-clinical development, with Phase 1/2a expected in early 2024.
Altevax's partnership with Assistance Publique Hôpitaux de Paris and other research institutions enables it to leverage their resources and accelerate clinical trials.
Altevax | A first-in-class immunotherapy against cancer
Using melanin as an adjuvant, Altevax has developed an immunotherapy that triggers a strong antigen-specific immune response of CD8+ and CD4+ T cells. Altevax is committed to bringing its innovative anticancer and anti-infectious technology to patients, to treat diseases that have no available cure today.
https://www.altevax.com/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 CIUS Government Administration | CIUS Government Administration | Other 29 May 2024 | | |
 | SATT AxLR | Other 29 May 2024 | | |
 BioValley France Public business cluster, Biotechnology, French Cluster, Biotechnology Research | BioValley France Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Other 29 May 2024 | | |
 Business France National and local authorities, Government Administration | Business France National and local authorities, Government Administration | Other 5 Jun 2024 | | |
 CNRS Research, Research Services | CNRS Research, Research Services | Other 22 May 2024 | | |
 Viva Technology Trade show, IT Services and IT Consulting | Viva Technology Trade show, IT Services and IT Consulting | Other 22 May 2024 | | |
 Sanofi Pharmaceutical, Pharmaceutical Manufacturing | Sanofi Pharmaceutical, Pharmaceutical Manufacturing | Other 22 May 2024 | | |
 CCI Paris IdF Chamber of commerce, Government Administration | CCI Paris IdF Chamber of commerce, Government Administration | Other 24 May 2024 | | |
 France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | Other 5 Jun 2024 | | |
 Medicen Paris Region Public business cluster, French Cluster, Civic and Social Organizations | Medicen Paris Region Public business cluster, French Cluster, Civic and Social Organizations | Other 5 Jun 2024 | | |